Company Overview
Omass Therapeutics Limited is listed at the official companies registry as Active Private Limited Company. The company was incorporated on Friday 26 February 2016, so this is a well established company. Omass Therapeutics Limited has been in business for 10 years and 1 month. The accounts status is full and the accounts are next due on Wednesday 30 September 2026.
Registered Address

Building 4000 John Smith Drive, Oxford Business Park South, Oxford, OX4 2GX
Credit Reports Available

These credit rating reports are available now:


Credit Analysts Report
Get Report >>

Standard Credit Report
Get Report >>

Basic Credit Report
Get Report >>

24/7 credit rating data feed - no UK company credit reports are updated faster

Companies House Data
Company NameOMASS THERAPEUTICS LIMITED
Company Number10028228
Registered Office AddressBuilding 4000 John Smith Drive
 Oxford Business Park South
 OX4 2GX
Company CategoryPrivate Limited Company
Company StatusActive
Country of OriginUnited Kingdom
Incorporation Date26/02/2016
Accounting Reference Date Day31
Accounting Reference Date Month12
Accounts Next Due Date30/09/2026
Accounts Last Made Up Date31/12/2024
Accounts Account CategoryFULL
Returns Next Due Date26/03/2017
Previous Company NameChanged Date
OMASS TECHNOLOGIES LIMITED21 Nov 2018
Directors & Members
Show Resigned
Christopher Ashton - Director
(British, 66 years old, born February 1960)
Appointed 14 October 2020
 Active
Diana Bernstein - Director
(American, 40 years old, born October 1986)
Appointed 19 April 2022
 Active
Scott Biller - Director
(American, 71 years old, born December 1955)
Appointed 19 April 2022
 Active
Laia Crespo-Martin - Director
(Spanish, 52 years old, born May 1974)
Appointed 19 April 2022
 Active
Rosamond Deegan - Director
(British, 53 years old, born February 1973)
Appointed 30 May 2019
 Active
Nathalie Franchimont - Director
(Belgian, 61 years old, born October 1965)
Appointed 23 July 2020
 Active
Edward Hodgkin - Director
(British, 63 years old, born August 1963)
Appointed 24 May 2017
 Active
Magdalena Jonikas - Director
(British, 42 years old, born April 1984)
Appointed 29 June 2018
 Active
Jonathan Montagu Daoust - Director
(British, 51 years old, born October 1975)
Appointed 30 May 2019
 Active
Carol Schafer - Director
(American, 63 years old, born August 1963)
Appointed 07 July 2025
 Active
Secretaries
Show Resigned
Other Company Directorships
Christopher Ashton
ACHILLES THERAPEUTICS UK LIMITED
ARGENTA DISCOVERY 2009 LIMITED
ETIOLOGICS LIMITED
MACROPHOX LTD
ORCHID CELLMARK LTD
PULMAGEN THERAPEUTICS (ASTHMA) LIMITED
PULMAGEN THERAPEUTICS (HOLDINGS) LIMITED
PULMAGEN THERAPEUTICS (INFLAMMATION) LIMITED
PULMAGEN THERAPEUTICS (SYNERGY) LIMITED
PULMAGEN THERAPEUTICS LLP
SYNCONA MANAGEMENT LLP
SYNCONA PARTNERS LLP
T-CYPHER BIO HOLDINGS LIMITED
T-CYPHER BIO LIMITED
Diana Bernstein
No companies found
Scott Biller
No companies found
Laia Crespo-Martin
No companies found
Rosamond Deegan
No companies found
Nathalie Franchimont
No companies found
Edward Hodgkin
AUTOLUS LIMITED
BIOINDUSTRY ASSOCIATION
BIOTICA TECHNOLOGY LIMITED
RESOLUTION THERAPEUTICS LIMITED
SVS RESEARCH HOLDINGS LIMITED
SVS RESEARCH LIMITED
SYNCONA MANAGEMENT LLP
SYNCONA PARTNERS LLP
Magdalena Jonikas
AZERIA THERAPEUTICS LIMITED
KESMALEA THERAPEUTICS LIMITED
MOSAIC THERAPEUTICS LIMITED
SYNCONA DISCOVERY LIMITED
Jonathan Montagu Daoust
No companies found
Carol Schafer
No companies found
Balance Sheet Unlock full report
Accounts Date 31-Dec-2024 31-Dec-2020 31-Dec-2019
Balance Sheet
Fixed Assets 3,611,024 3,611,024 1,145,138
Current Assets 12,560,803 12,560,803 9,154,365
Creditors Due Within One Year 2,270,030 2,270,030 1,134,467
Working Cap 10,290,773 10,290,773 8,019,898
Total Assets Less Current Liabilities 13,901,797 13,901,797 9,165,036
Long-term Liabilities 9,999 9,999 74,998
Net Assets 13,891,798 13,891,798 9,090,038
Share Capital & Reserves
Share Cap - - -
Profit & Loss Reserves - - -
Other Reserves - - -
Shareholders Funds 13,891,798 13,891,798 9,090,038
Common Size Financial Analysis Unlock full report
Accounts Date 31-Dec-2024 31-Dec-2020 31-Dec-2019
Tangible Fixed Assets - - -
Fixed Assets 22.3% 22.3% 11.1%
Stocks Inventory - - -
Debtors 0.0% 0.0% 0.0%
Cash Bank In Hand 62.2% 62.2% 76.0%
Current Assets 77.7% 77.7% 88.9%
Creditors Due Within One Year 14.0% 14.0% 11.0%
Net Current Assets Liabilities 63.6% 63.6% 77.9%
Creditors Due After One Year - - -
Accruals Deferred Income - - -
Provisions For Liabilities Charges - - -
Net Assets Liabilities Including Pension Asset Liability - - -
Called Up Share Capital - - -
Share Capital Allotted Called Up Paid - - -
Profit Loss Account Reserve - - -
Shareholder Funds 85.9% 85.9% 88.3%
Capital Employed - - -
Total Assets Less Current Liabilities 86.0% 86.0% 89.0%
Financial Ratio Analysis Unlock full report
Accounts Date 31-Dec-2024 31-Dec-2020 31-Dec-2019
Liquidity Ratio 5.5 5.5 8.1
Solvency Ratio 7.1 7.1 8.5
Reserves to Assets - - -
Secured Creditors Unlock full report
Mortgages Charges 1
Mortgages Outstanding 0
Mortgages Part Satisfied 0
Mortgages Satisfied 1
Assets and Debt Analysis Unlock full report
Accounts Date 31-Dec-2024 31-Dec-2020 31-Dec-2019
Assets 16,171,827 16,171,827 10,299,503
Debt 2,280,029 2,280,029 1,209,465
Net Assets/Debt 13,891,798 13,891,798 9,090,038

The following is based on the accounts data presented in this report sourced from Companies House, however the company has filed later accounts. Our analysis of the latest account can be viewed by unlocking our full report.

The company balance sheet displays a comfortable surplus of working capital. We would normally view this positively. Total reserves including retained profitability and movement in reserves appeared positive. We would normally view a company positively for this. The balance sheet indicates the net assets of a good sized company. For the size of the company inferred by the balance sheet the level of net assets suggests a comfortable level of cover for total debts and obligations.

Unlock full report  The following is based on the accounts data presented in this report sourced from Companies House, however the company has filed later accounts. Our analysis of the latest account can be viewed by unlocking our full report.The company balance sheet displays a comfortable surplus of working capital. We would normally view this positively. Total reserves including retained profitability and movement in reserves appeared positive. We would normally view a company positively for this. The balance sheet indicates the net assets of a good sized company. For the size of the company inferred by the balance sheet the level of net assets suggests a comfortable level of cover for total debts and obligations.   The following is based on the accounts data presented in this report sourced from Companies House, however the company has filed later accounts. Our analysis of the latest account can be viewed by unlocking our full report.The company balance sheet displays a comfortable surplus of working capital. We would normally view this positively. Total reserves including retained profitability and movement in reserves appeared positive. We would normally view a company positively for this. The balance sheet indicates the net assets of a good sized company. For the size of the company inferred by the balance sheet the level of net assets suggests a comfortable level of cover for total debts and obligations.

This review of public record balance sheet and company status information is presented under the terms of Open Government Licence and is for informational purposes only, is general in nature, and is not intended as an opinion or advice for any specific circumstances. The commentary and the colour band score is not a credit rating or credit risk assessment.

This review does not constitute a full credit rating or credit risk assessment based on the full analysis and credit score algorithms used in our credit reports. A full credit report may also provide information relating to trade payment history and county court or court judgments if any.

Public Record Information Unlock full report
Exact Court Judgements
Period of Months Last 12m 13-24m 25-36m 37-48m 49-60m 61-72m
Number of Exact CCJS X Y Y X X Y
Value of Exact CCJS YXY YK S S X KX
Supplier Credit Limits Unlock full report
Date Sector Notified Amount Terms
XK-SXY XKXYXK SXSKXYXK £X,000 XS XYSKS
SK-SYY SKXYXKYKKY KSXX KKXXYXS £YY,000 YS XYSKS SK YXXSXS
YK-SXY XKXYXYYK SXSXYXK £SX,000 XS XYSKS
Payment Records Unlock full report
Payment Records from it's suppliers' company ledger show how a company is paying its suppliers

Payment Analysis

Total Invoices Paid Before
30 days due		 Paid After
30 days due		 Owing Before
30 days due		 Owing after
30 days due
XYX SX K YX X
Company Valuation Analysis Unlock full report

Going Concern Valuation

The going concern valuations value the company on the basis that it continues to trade without the threat of liquidation for the foreseeable future. These valuations are primarily profit and cashflow based.

Valuations Valuation Measures
Estimated High Value £XSI,000 Retained Profit £YX,000
Estimated Mid Value £YY,000 EBIT £SY,000
Estimated Low Value £X,000 EBITDA £SSX,000

Liquidation Valuation

The liquidaton valuation values the company as if it were to cease trading and assets were subject to rapid disposal to cover liabilities. This valuation is primarily asset based.

Valuations Valuation Measures
Estimated High Value £XY,000 Total Assets £XIX,000
Estimated Mid Value £Y,000 Net Assets £YX,000
Estimated Low Value £S,000 Tangible Equity £SX,000

The above valuations are based on our own algorithms and take no account of many factors that can influence actual valuations realized and should not therefore be assumed to be accurate.
Credit Status Checklist Unlock full report
Business Growth Please purchase a report to see true comments
EBITDA Purchase a report to see true comments
Dividends Please purchase a report to see true comments about this company
Retained Profits Retained Profits for this company
Debt Interest Debt Interest for this company
Cash Flow Cash Flow for this company
CCJs CCJs for this company
Age of Company Age of Company for this company
Solvency Solvency for this company
Secured Creditors Secured Creditors for this company
Ownership Ownership for this company


First Report Score: (0-10) X
Financial Status Guide:
10 Very Strong
9 Strong
8 Very Good
7 Good
6 Above Average
5 Average
4 Below Average
3 Poor
2 Weak
1 Very Weak
0 Critical

Risk Score Trend

Risk Rating Unlock full report

This is the credit risk assessment used by one of the top UK credit reference agencies.

Risk Score (1-100) X
Risk Band Description XXMXMXMX SISX
Risk Assessment Meeting of Creditors
Credit Rating XSKX
Altman Z Score Credit Risk Rating Unlock full report

There have been many bankruptcy predictors developed, however none has been so thoroughly tested and broadly accepted as the Altman Z-Score.

Z Score X
Risk Band XY
Risk Band Description The Z Score is not used for small companies where full accounts are not filed because profit and loss account items are required to calculate the score.

Z Score Bands

1 Low Risk 3.00 and above
2 Caution 2.63 - 2.99
3 Risk of Failure within 2 years 1.24 - 2.62
4 High Probability Failure Below 1.24
Other Business around OX4 2GX
FROST & SULLIVAN, LIMITED
GROUND FLOOR BUILDING 11 CHISWICK BUSINESS PARK, 566 CHISWICK HIGH ROAD, LONDON, OX4 2GX
Document Filings
Termination of appointment of James Arthur Geraghty as a director on 17 March 2026
Confirmation statement made on 12 March 2026 with updates
Cessation of Oxford Science Enterprises Holdings Ii Limited as a person with significant control on 11 September 2018
Change of details for Oxford Science Enterprises Holdings Ii Limited as a person with significant control on 11 September 2018
Change of details for Oxford Science Enterprises Plc as a person with significant control on 12 February 2026
Notification of Oxford Science Enterprises Holdings Ii Limited as a person with significant control on 11 September 2018
Change of details for Oxford Science Enterprises Holdings Ii Limited as a person with significant control on 11 September 2018
Change of details for Oxford Science Enterprises Plc as a person with significant control on 12 February 2026
Termination of appointment of Birgitte Volck as a director on 9 February 2026
Statement of capital following an allotment of shares on 30 January 2026
Change of share class name or designation
Statement of capital following an allotment of shares on 5 December 2025
Change of share class name or designation
Change of share class name or designation
Statement of capital following an allotment of shares on 28 October 2025
Change of share class name or designation
Change of share class name or designation
Appointment of Ms Carol Anne Schafer as a director on 7 July 2025
Appointment of Dr Birgitte Volck as a director on 1 February 2025
Confirmation statement made on 12 March 2025 with updates
Resolutions
Memorandum and Articles of Association
Change of share class name or designation
Terms and Conditions Cancellations Contact Us

In using this service you agree to the Terms and Conditions

© 2026 Check Free